Cargando…

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of the Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited Apellis Pharmaceuticals/Sobi to submit evidence for the clinical and cost effectiveness of pegcetacoplan versus eculizumab and pegcetacoplan versus ravulizumab for treati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bresnahan, Rebecca, Houten, Rachel, Greenhalgh, Janette, Nevitt, Sarah, Mahon, James, Beale, Sophie, Boland, Angela, Bhattacharyya, Devarshi, Dundar, Yenal, McEntee, Joanne, Gandhi, Shreyans, Fleeman, Nigel, Chaplin, Marty
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333166/ https://www.ncbi.nlm.nih.gov/pubmed/37195551 http://dx.doi.org/10.1007/s41669-023-00408-z

Ejemplares similares

Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2020)

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A
Publicado: (2022)

Correction to: Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria
por: Heo, Young-A.
Publicado: (2023)

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2023)

Normalisation of haemoglobin and control of breakthrough haemolysis with increased frequency pegcetacoplan dosing in treated paroxysmal nocturnal haemoglobinuria
por: Davis, Amanda K., et al.
Publicado: (2023)

Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Lambe, Tosin, et al.
Publicado: (2018)

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Fleeman, Nigel, et al.
Publicado: (2019)

Coombs-positive Paroxysmal Nocturnal Haemoglobinuria
por: Kalam, Sabrina, et al.
Publicado: (2020)

Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma: A NICE Single Technology Appraisal
por: Greenhalgh, Janette, et al.
Publicado: (2013)

PB2043: CLINICAL EFFECTIVENESS, TREATMENT USE, SATISFACTION AND IMPACT ON QUALITY-OF-LIFE OF PEGCETACOPLAN TREATMENT FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA (PNH).
por: Wilson, Koo, et al.
Publicado: (2023)

Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S.M.
Publicado: (2022)

Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022)

Paroxysmal nocturnal haemoglobinuria and diabetes mellitus.
por: Andrews, W. J., et al.
Publicado: (1990)

Paroxysmal Nocturnal Haemoglobinuria: Clinical-Pathological Conference
por: Hewer, T. F.
Publicado: (1963)

Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria
por: Rehan, Syeda Tayyaba, et al.
Publicado: (2022)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022)

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
por: Cançado, Rodolfo D., et al.
Publicado: (2021)

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab
por: de Castro, Carlos, et al.
Publicado: (2020)

PB2054: EXPOSURE-RESPONSE ANALYSES OF PEGCETACOPLAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond Siu Ming, et al.
Publicado: (2023)

Tozinameran: Flare up of paroxysmal nocturnal haemoglobinuria: case report
Publicado: (2022)

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria
por: Wong, Raymond S. M., et al.
Publicado: (2022)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
por: Ping, Haili, et al.
Publicado: (2023)

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA
por: Fishman, Jesse, et al.
Publicado: (2023)

Primary myelofibrosis with concurrent paroxysmal nocturnal haemoglobinuria presenting with erectile dysfunction
por: Alsalman, Zaenb, et al.
Publicado: (2022)

How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future
por: Risitano, Antonio Maria, et al.
Publicado: (2021)

Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
por: Adhikari, Sugat, et al.
Publicado: (2023)

P794: EVALUATION OF PEGCETACOPLAN IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH APLASTIC ANEMIA IN THE PRINCE STUDY
por: Bogdanovic, Andrija, et al.
Publicado: (2023)

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events
por: Dragoni, Francesco, et al.
Publicado: (2018)

Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
por: Moriyama, Mitsuru, et al.
Publicado: (2021)

Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Stainthorpe, Angela, et al.
Publicado: (2018)

Paroxysmal Hæmoglobinuria
Publicado: (1910)

Paroxysmal Hæmoglobinuria
Publicado: (1903)

Paroxysmal Hæmoglobinuria
por: Campbell, F. R.
Publicado: (1887)

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria
por: Hillmen, Peter, et al.
Publicado: (2013)

The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review
por: Devalet, Bérangère, et al.
Publicado: (2014)

Paroxysmal nocturnal haemoglobinuria (PNH) manifesting on CT as a pathologic segment of small bowel
por: Zekria, David, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_83tmg0ar94v6j5s9thn1nvj8fk